kyowa Kirin
Update in progress4151.T (Tokyo)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Kyowa Kirin is a global pharmaceutical company that conducts research, development, manufacturing, and marketing of medicines. It markets Ziftomenib for adult relapsed/refractory AML with NPM1 mutation and Lumicef for palmoplantar pustulosis. It also has multiple active programs (Phase I–III) including rocatinlimab, infigratinib, OTL-203, OTL-201, and several KK assets for various diseases. It collaborates with La Jolla Institute, AstraZeneca, and Amgen. Based in Chiyoda, Tokyo, and a Kirin Holdings subsidiary. Formerly Kyowa Hakko Kirin; renamed in 2019.
Company score
- Sentiment
- 0.23
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.03
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.16
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketTokyo (JPX)
- LocationJapan
- CEODr. Abdul Hafeez Mullick Ph.D.
- Founded1949
- Employees5,173
- Websitewww.kyowakirin.com
Identifiers
- ISINJP3256000005